Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer

J. N. Ingle; D. I. Twito; D. J. Schaid; S. A. Cullinan; J. E. Krook; J. A. Mailliard; R. F. Marschke; H. J. Long; J. G. Gerstner; H. E. Windschitl; L. K. Everson; D. M. Pfeifle

doi:10.1200/JCO.1988.6.5.825

Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer

J. N. Ingle, D. I. Twito, D. J. Schaid, S. A. Cullinan, J. E. Krook, J. A. Mailliard, R. F. Marschke, H. J. Long, J. G. Gerstner, H. E. Windschitl, L. K. Everson, D. M. Pfeifle

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious that TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 TAM patients (42%) and 63 of 119 TAM plus FLU patients (53%) (one-sided P = .05). Time to disease progression distributions were better for TAM plus FLU (median, 350 days v 199 days), but the log rank test only approached statistical significance (one-sided P = .07). Duration of response and survival distributions were similar between the two treatment arms. Toxicities, in terms of androgenic side effects, were greater on the TAM plus FLU regimen. Fifty-two patients are evaluable for response with FLU following TAM and 21 (40%) have acieved a response. We conclude that the advantages in terms of response rate and time to progression observed with TAM plus FLU probably represent a biological effect, but are not of sufficient magnitude to justify the routine clinical use of this combination given the lack of survival advantage and side effects encountered.

Original language	English (US)
Pages (from-to)	825-831
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	6
Issue number	5
DOIs	https://doi.org/10.1200/JCO.1988.6.5.825
State	Published - 1988

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.1988.6.5.825

Cite this

Ingle, J. N., Twito, D. I., Schaid, D. J., Cullinan, S. A., Krook, J. E., Mailliard, J. A., Marschke, R. F., Long, H. J., Gerstner, J. G., Windschitl, H. E., Everson, L. K., & Pfeifle, D. M. (1988). Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. Journal of Clinical Oncology, 6(5), 825-831. https://doi.org/10.1200/JCO.1988.6.5.825

Ingle, JN, Twito, DI, Schaid, DJ, Cullinan, SA, Krook, JE, Mailliard, JA, Marschke, RF, Long, HJ, Gerstner, JG, Windschitl, HE, Everson, LK & Pfeifle, DM 1988, 'Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer', Journal of Clinical Oncology, vol. 6, no. 5, pp. 825-831. https://doi.org/10.1200/JCO.1988.6.5.825

@article{ff552fa40df549628bf2d0ed4fa5f971,

title = "Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer",

abstract = "A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious that TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 TAM patients (42%) and 63 of 119 TAM plus FLU patients (53%) (one-sided P = .05). Time to disease progression distributions were better for TAM plus FLU (median, 350 days v 199 days), but the log rank test only approached statistical significance (one-sided P = .07). Duration of response and survival distributions were similar between the two treatment arms. Toxicities, in terms of androgenic side effects, were greater on the TAM plus FLU regimen. Fifty-two patients are evaluable for response with FLU following TAM and 21 (40%) have acieved a response. We conclude that the advantages in terms of response rate and time to progression observed with TAM plus FLU probably represent a biological effect, but are not of sufficient magnitude to justify the routine clinical use of this combination given the lack of survival advantage and side effects encountered.",

author = "Ingle, {J. N.} and Twito, {D. I.} and Schaid, {D. J.} and Cullinan, {S. A.} and Krook, {J. E.} and Mailliard, {J. A.} and Marschke, {R. F.} and Long, {H. J.} and Gerstner, {J. G.} and Windschitl, {H. E.} and Everson, {L. K.} and Pfeifle, {D. M.}",

year = "1988",

doi = "10.1200/JCO.1988.6.5.825",

language = "English (US)",

volume = "6",

pages = "825--831",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

TY - JOUR

T1 - Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer

AU - Ingle, J. N.

AU - Twito, D. I.

AU - Schaid, D. J.

AU - Cullinan, S. A.

AU - Krook, J. E.

AU - Mailliard, J. A.

AU - Marschke, R. F.

AU - Long, H. J.

AU - Gerstner, J. G.

AU - Windschitl, H. E.

AU - Everson, L. K.

AU - Pfeifle, D. M.

PY - 1988

Y1 - 1988

N2 - A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious that TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 TAM patients (42%) and 63 of 119 TAM plus FLU patients (53%) (one-sided P = .05). Time to disease progression distributions were better for TAM plus FLU (median, 350 days v 199 days), but the log rank test only approached statistical significance (one-sided P = .07). Duration of response and survival distributions were similar between the two treatment arms. Toxicities, in terms of androgenic side effects, were greater on the TAM plus FLU regimen. Fifty-two patients are evaluable for response with FLU following TAM and 21 (40%) have acieved a response. We conclude that the advantages in terms of response rate and time to progression observed with TAM plus FLU probably represent a biological effect, but are not of sufficient magnitude to justify the routine clinical use of this combination given the lack of survival advantage and side effects encountered.

AB - A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious that TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 TAM patients (42%) and 63 of 119 TAM plus FLU patients (53%) (one-sided P = .05). Time to disease progression distributions were better for TAM plus FLU (median, 350 days v 199 days), but the log rank test only approached statistical significance (one-sided P = .07). Duration of response and survival distributions were similar between the two treatment arms. Toxicities, in terms of androgenic side effects, were greater on the TAM plus FLU regimen. Fifty-two patients are evaluable for response with FLU following TAM and 21 (40%) have acieved a response. We conclude that the advantages in terms of response rate and time to progression observed with TAM plus FLU probably represent a biological effect, but are not of sufficient magnitude to justify the routine clinical use of this combination given the lack of survival advantage and side effects encountered.

UR - http://www.scopus.com/inward/record.url?scp=0023935682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023935682&partnerID=8YFLogxK

U2 - 10.1200/JCO.1988.6.5.825

DO - 10.1200/JCO.1988.6.5.825

M3 - Article

C2 - 3284975

AN - SCOPUS:0023935682

SN - 0732-183X

VL - 6

SP - 825

EP - 831

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -

Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this